Gene Expression of Endocannabinoid System in Episodic and Chronic Migraine Patients
NCT ID: NCT04324710
Last Updated: 2020-03-27
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
75 participants
Study Classification
OBSERVATIONAL
Study Start Date
2017-12-12
Study Completion Date
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Preclinical and clinical evidence suggests a role for the dysregulation of endocannabinoid system (ES) in migraine pain, particularly in subjects with chronic migraine.
The gene expression of ES components were assayed in peripheral blood mononuclear cells (PBMCs) of patients with episodic migraine (EM), chronic migraine with medication overuse (CM-MO) and age-matched healthy controls (CT). It was evaluated the protein expression of cannabinoid receptors (CB) 1 and 2 as well as DNA methylation changes in genes involved in ES components.
The gene expression of ES components were assayed in peripheral blood mononuclear cells (PBMCs) of patients with episodic migraine (EM), chronic migraine with medication overuse (CM-MO) and age-matched healthy controls (CT). It was evaluated the protein expression of cannabinoid receptors (CB) 1 and 2 as well as DNA methylation changes in genes involved in ES components.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Mindfulness Therapy for Chronic Migraine
NCT03671681
Chronic Migraine
Medication Overuse Headache
COMPLETED
PHASE4
Searching for Novel Therapeutic Approaches in Migraine Patients Resistant to Treatments
NCT06562400
Migraine Disorders
Chronic Migraine
Episodic Migraine
RECRUITING
Pain Control in Episodic and Chronic Migraine
NCT06599905
Migraine
COMPLETED
NA
Biochemical Profiling of Migraine Patients
NCT06549270
Migraine Disorders
Chronic Migraine
Episodic Migraine
RECRUITING
Neurophysiological, Biomolecular and Psychological Aspects of Erenumab Treatment in Chronic Migraine
NCT04361721
Chronic Migraine
UNKNOWN
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Migraine is a neurovascular disease whose pathophysiology is far from being completely clarified. This is mainly due to the complex mechanisms that underlie migraine attack as well as its recurrence. The endocannabinoid system (ES) is a complex signalling system involved in different biological processes (e.g. neuronal activity, pain sensation and immune functions) and it plays a crucial role in the maintenance of body homeostasis. The ES components include the endogenous lipids, the most studied ones being N-arachidonoylethanolamide (AEA) and 2-arachidonoylglycerol (2-AG), their metabolic enzymes and at least two cannabinoid receptors (CB1 and CB2). The biosynthesis of AEA mainly occurs by N-acylphosphatidylethanolamide-phospholipase D (NAPE-PLD), whereas 2-AG is produced through the action of diacylglycerol lipase (DAGL). AEA is metabolized by fatty acid amide hydrolase (FAAH) and 2-AG mainly by monoacylglycerol lipase (MAGL).
Alterations in gene expression of ES components may involve various cell types, multiple catabolic pathways and the generation of active metabolites via epigenetic mechanisms, under both physiological and pathological conditions. CB genes, for instance, may interact with different transcriptional factors, many of which are related to DNA methylation and histone post-translational modifications. A dysfunctional ES has been associated to numerous disorders including migraine. The ES, indeed, modulates multiple activities and neuromodulators/neurotransmitters that play a crucial role in migraine pathogenesis. ES is also implicated in the descending modulation of the trigeminovascular nociceptive transmission from the brainstem afferents. Previous studies from the Laboratory of Neurophysiology of Integrative Autonomic Systems, Headache Science Centre, IRCCS Mondino Foundation, Pavia (Italy), using the migraine-specific animal model based on nitroglycerin administration in rat, demonstrated the existence of interactions between the ES and pain mediation. In particular, the investigators showed a key role for AEA and for FAAH-regulated AEA activity in the processing of trigeminal nociceptive signals. AEA inhibits neurogenic dural vasodilatation, as well as calcitonin gene-related peptide-induced and nitric oxide-induced dural vessel dilation, an activity that is reversed by CB1 antagonism. The interaction between the ES and migraine pain is also suggested by clinical observations. FAAH activity was higher in platelets of women with episodic migraine (EM) to suggest a more marked degradation of AEA. Subjects with chronic migraine (CM) and medication overuse (MO) showed an altered endocannabinoid metabolism not only in platelets, but also in the CSF. Although the above clinical findings are scattered and replicated, their re-consideration in the light of more recent data from the increasing pre-clinical evidence prompt the need to investigate in more depth the role of ES in migraine pathophysiology.
Several studies suggest that changes in ES components detected in peripheral blood mononuclear cells (PBMCs) are reliable indicators of a central dysfunction of the ES in different neurological diseases. For instance, in patients with Parkinson disease or multiple sclerosis, increased CSF levels of AEA were associated with a reduction in the activity and protein content of FAAH in PBMCs, which is indicative of an increased AEA tone. AEA levels were elevated in the CSF and in the blood of schizophrenic subjects, with a significant drop in AEA blood levels and in mRNA transcripts of CB2 and FAAH in PBMCs following clinical remission.
The aim of this study, was the identification of specific functional patterns of ES activity in subjects with migraine. To this end, the investigators performed a thorough evaluation of multiple peripheral components of the ES (gene expression, protein expression and DNA methylation) in PBMCs of representative samples of subjects with EM without aura, CM-MO and in healthy controls (CT).
Twenty-five subjects with EM, 26 with CM-MO and 24 CT were enrolled in the headache center of the IRCCS Mondino Foundation of Pavia (Italy). The study was approved by the local Ethics Committee and all subjects enrolled signed a written informed consent.
Blood samples (20ml) were collected within ethylenediamine tetra-acetic acid (EDTA) containing tubes from participants. Blood samples were diluted in 1:1 ratio with phosphate buffer saline 1X (PBS 1X) (Sigma). Diluted blood samples were slowly loaded onto Ficoll separating solution (15ml) (Sigma) and centrifuged at 800 g without brake for 30 min at room temperature. PBMCs accumulated as the middle white monolayer, were washed twice in sterile PBS 1X and centrifuged at 300 g for 15 min. For each sample, a batch of PBMCs was used for RNA or DNA extraction and another one for flow-cytometer analysis.
In the PBMCs isolated from the subjects in the 3 study groups the investigators assayed:
* CB1 and CB2 protein expression;
* expression of the following genes: CB receptors, FAAH, NAPE-PLD, MAGL and DAGL
* DNA methylation of ES components. To determine the relative level of CB1 and CB2 protein expression in PBMCs, the investigators used flow-cytometry with a FACS Canto flow-cytometer (Becton-Dickenson). After isolation, cells (100000 per reaction) were stained using antibodies against CD45 (BD Biosciences, 1:50), CB1 (R\&D system, 1:50) and CB2 receptors (Cayman Chemical, 1:30); a total of 10000 events were counted in windows gated for the intersection of CD45 staining with CB1 and CB2.
Total RNA from PBMCs was isolated using standard procedure (Zymo Research) and RNA quality was assessed using a nanodrop spectrophotometer (Nanodrop™ Thermo Fisher Scientific); cDNA was generated using the iScript cDNA Synthesis kit (Biorad) following the supplier's instructions. Gene expression of CB receptors, FAAH, NAPE-PLD, MAGL and DAGL was analyzed using the Fast Eva Green supermix (BIO-RAD). Ubiquitin (UBC), whose expression remained constant in all experimental groups, was used as housekeeping gene. The amplification was performed with a light Cycler 480 Instrument rt-PCR Detection System (Roche) following the supplier's instructions. All samples were assayed in triplicate and gene expression levels were calculated according to 2-∆Ct = 2- (Ct gene - Ct housekeeping gene) formula by using Ct values.
Since PBMCs contain the full complement of epigenetic enzymes found in most tissues, including neurons and peripheral nucleated cells, the investigators evaluated the role of DNA methylation in the regulation of ES gene transcription in all the enrolled subjects.
DNA was extracted from whole blood using QIAmp DNA Blood Mini Kit (Qiagen) and its concentration was determined by NanoDrop quantification (NanoDrop Techologies, Thermofisher). Arrays preparation and data analysis were performed by Genomix4Life srl (Baronissi, Italy). High-quality DNA (500 ng) was bisulfite converted using EZ DNA methylation kit (Zymo Research, Irvine, CA, USA). Bisulfite converted DNA (200ng) was used for analysis of whole-genome methylation, using the HumanMethylation 450 K BeadChip (Illumina, San Diego, CA, USA), which contains 485 577 probes covering 21 231 (99%) RefSeq genes. In brief, bisulfite converted DNA was whole-genome amplified for 20 h followed by end-point fragmentation. Fragmented DNA was precipitated, denatured and hybridised to the BeadChips for 20 h at 48 °C. The BeadChips were washed and the hybridised primers were extended and labelled before scanning the BeadChips using the Illumina iScan system. GenomeStudio software (version 2011.1; Illumina Inc.) was used for the extraction of DNA methylation signals from scanned arrays. The methylation level for each cytosine was expressed as a beta value calculated as the fluorescence intensity ratio of the methylated to unmethylated versions of the probes: beta values ranged between 0 (unmethylated) and 1 (methylated). The annotation relating to CGIs uses the following categorisation: 'shore', each of the 2-kb sequences flanking a CGI; 'shelf', each of the 2-kb sequences next to a shore; 'open sea', DNA not included in any of the previous sequences or in CGIs 4. TSS200 and TSS1500 indicate the region between position -200 bp and -1500 bp from the TSS, respectively. The significant methylation difference between two given loci is indicated by a delta-beta value and determined with GenomeStudio Methylation Module using Illumina custom algorithm for calculating DiffScores (DiffScore⩽-30.0 (≈ pval \<0.001)=hypo-methylation; DiffScore⩾30.0 (≈ p val\<0.001)=hyper-methylation).
Alterations in gene expression of ES components may involve various cell types, multiple catabolic pathways and the generation of active metabolites via epigenetic mechanisms, under both physiological and pathological conditions. CB genes, for instance, may interact with different transcriptional factors, many of which are related to DNA methylation and histone post-translational modifications. A dysfunctional ES has been associated to numerous disorders including migraine. The ES, indeed, modulates multiple activities and neuromodulators/neurotransmitters that play a crucial role in migraine pathogenesis. ES is also implicated in the descending modulation of the trigeminovascular nociceptive transmission from the brainstem afferents. Previous studies from the Laboratory of Neurophysiology of Integrative Autonomic Systems, Headache Science Centre, IRCCS Mondino Foundation, Pavia (Italy), using the migraine-specific animal model based on nitroglycerin administration in rat, demonstrated the existence of interactions between the ES and pain mediation. In particular, the investigators showed a key role for AEA and for FAAH-regulated AEA activity in the processing of trigeminal nociceptive signals. AEA inhibits neurogenic dural vasodilatation, as well as calcitonin gene-related peptide-induced and nitric oxide-induced dural vessel dilation, an activity that is reversed by CB1 antagonism. The interaction between the ES and migraine pain is also suggested by clinical observations. FAAH activity was higher in platelets of women with episodic migraine (EM) to suggest a more marked degradation of AEA. Subjects with chronic migraine (CM) and medication overuse (MO) showed an altered endocannabinoid metabolism not only in platelets, but also in the CSF. Although the above clinical findings are scattered and replicated, their re-consideration in the light of more recent data from the increasing pre-clinical evidence prompt the need to investigate in more depth the role of ES in migraine pathophysiology.
Several studies suggest that changes in ES components detected in peripheral blood mononuclear cells (PBMCs) are reliable indicators of a central dysfunction of the ES in different neurological diseases. For instance, in patients with Parkinson disease or multiple sclerosis, increased CSF levels of AEA were associated with a reduction in the activity and protein content of FAAH in PBMCs, which is indicative of an increased AEA tone. AEA levels were elevated in the CSF and in the blood of schizophrenic subjects, with a significant drop in AEA blood levels and in mRNA transcripts of CB2 and FAAH in PBMCs following clinical remission.
The aim of this study, was the identification of specific functional patterns of ES activity in subjects with migraine. To this end, the investigators performed a thorough evaluation of multiple peripheral components of the ES (gene expression, protein expression and DNA methylation) in PBMCs of representative samples of subjects with EM without aura, CM-MO and in healthy controls (CT).
Twenty-five subjects with EM, 26 with CM-MO and 24 CT were enrolled in the headache center of the IRCCS Mondino Foundation of Pavia (Italy). The study was approved by the local Ethics Committee and all subjects enrolled signed a written informed consent.
Blood samples (20ml) were collected within ethylenediamine tetra-acetic acid (EDTA) containing tubes from participants. Blood samples were diluted in 1:1 ratio with phosphate buffer saline 1X (PBS 1X) (Sigma). Diluted blood samples were slowly loaded onto Ficoll separating solution (15ml) (Sigma) and centrifuged at 800 g without brake for 30 min at room temperature. PBMCs accumulated as the middle white monolayer, were washed twice in sterile PBS 1X and centrifuged at 300 g for 15 min. For each sample, a batch of PBMCs was used for RNA or DNA extraction and another one for flow-cytometer analysis.
In the PBMCs isolated from the subjects in the 3 study groups the investigators assayed:
* CB1 and CB2 protein expression;
* expression of the following genes: CB receptors, FAAH, NAPE-PLD, MAGL and DAGL
* DNA methylation of ES components. To determine the relative level of CB1 and CB2 protein expression in PBMCs, the investigators used flow-cytometry with a FACS Canto flow-cytometer (Becton-Dickenson). After isolation, cells (100000 per reaction) were stained using antibodies against CD45 (BD Biosciences, 1:50), CB1 (R\&D system, 1:50) and CB2 receptors (Cayman Chemical, 1:30); a total of 10000 events were counted in windows gated for the intersection of CD45 staining with CB1 and CB2.
Total RNA from PBMCs was isolated using standard procedure (Zymo Research) and RNA quality was assessed using a nanodrop spectrophotometer (Nanodrop™ Thermo Fisher Scientific); cDNA was generated using the iScript cDNA Synthesis kit (Biorad) following the supplier's instructions. Gene expression of CB receptors, FAAH, NAPE-PLD, MAGL and DAGL was analyzed using the Fast Eva Green supermix (BIO-RAD). Ubiquitin (UBC), whose expression remained constant in all experimental groups, was used as housekeeping gene. The amplification was performed with a light Cycler 480 Instrument rt-PCR Detection System (Roche) following the supplier's instructions. All samples were assayed in triplicate and gene expression levels were calculated according to 2-∆Ct = 2- (Ct gene - Ct housekeeping gene) formula by using Ct values.
Since PBMCs contain the full complement of epigenetic enzymes found in most tissues, including neurons and peripheral nucleated cells, the investigators evaluated the role of DNA methylation in the regulation of ES gene transcription in all the enrolled subjects.
DNA was extracted from whole blood using QIAmp DNA Blood Mini Kit (Qiagen) and its concentration was determined by NanoDrop quantification (NanoDrop Techologies, Thermofisher). Arrays preparation and data analysis were performed by Genomix4Life srl (Baronissi, Italy). High-quality DNA (500 ng) was bisulfite converted using EZ DNA methylation kit (Zymo Research, Irvine, CA, USA). Bisulfite converted DNA (200ng) was used for analysis of whole-genome methylation, using the HumanMethylation 450 K BeadChip (Illumina, San Diego, CA, USA), which contains 485 577 probes covering 21 231 (99%) RefSeq genes. In brief, bisulfite converted DNA was whole-genome amplified for 20 h followed by end-point fragmentation. Fragmented DNA was precipitated, denatured and hybridised to the BeadChips for 20 h at 48 °C. The BeadChips were washed and the hybridised primers were extended and labelled before scanning the BeadChips using the Illumina iScan system. GenomeStudio software (version 2011.1; Illumina Inc.) was used for the extraction of DNA methylation signals from scanned arrays. The methylation level for each cytosine was expressed as a beta value calculated as the fluorescence intensity ratio of the methylated to unmethylated versions of the probes: beta values ranged between 0 (unmethylated) and 1 (methylated). The annotation relating to CGIs uses the following categorisation: 'shore', each of the 2-kb sequences flanking a CGI; 'shelf', each of the 2-kb sequences next to a shore; 'open sea', DNA not included in any of the previous sequences or in CGIs 4. TSS200 and TSS1500 indicate the region between position -200 bp and -1500 bp from the TSS, respectively. The significant methylation difference between two given loci is indicated by a delta-beta value and determined with GenomeStudio Methylation Module using Illumina custom algorithm for calculating DiffScores (DiffScore⩽-30.0 (≈ pval \<0.001)=hypo-methylation; DiffScore⩾30.0 (≈ p val\<0.001)=hyper-methylation).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Chronic Migraine
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. satisfaction of the diagnostic criteria for migraine without aura according to the International Headache Classification 3rd edition (ICHD-3);
2. an episodic pattern of migraine for at least 10 years without any period of chronification.
1. satisfaction of the ICHD-3 diagnostic criteria for chronic migraine and for one of the subtypes of medication overuse headache;
2. a history of stable chronification for at least 5 years.
1. no history of migraine or other primary headaches;
2. Infrequent tension-type headache episodes.
2. an episodic pattern of migraine for at least 10 years without any period of chronification.
1. satisfaction of the ICHD-3 diagnostic criteria for chronic migraine and for one of the subtypes of medication overuse headache;
2. a history of stable chronification for at least 5 years.
1. no history of migraine or other primary headaches;
2. Infrequent tension-type headache episodes.
Exclusion Criteria
any systemic diseases, psychiatric disorders or any other clinically significant conditions.
any systemic diseases, psychiatric disorders or any other clinically significant conditions.
1. any systemic diseases, psychiatric disorders or any other clinically significant conditions;
2. any type of painkiller in the 24 hours prior to the blood sampling.
any systemic diseases, psychiatric disorders or any other clinically significant conditions.
1. any systemic diseases, psychiatric disorders or any other clinically significant conditions;
2. any type of painkiller in the 24 hours prior to the blood sampling.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ministry of Health, Italy
OTHER_GOV
Sponsor Role
collaborator
IRCCS National Neurological Institute "C. Mondino" Foundation
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cristina Tassorelli, MD
Role: PRINCIPAL_INVESTIGATOR
IRCCS MONDINO FOUNDATION
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ircss Mondino Foundation
Pavia, , Italy
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Italy
References
Explore related publications, articles, or registry entries linked to this study.
Basavarajappa BS, Nixon RA, Arancio O. Endocannabinoid system: emerging role from neurodevelopment to neurodegeneration. Mini Rev Med Chem. 2009 Apr;9(4):448-62. doi: 10.2174/138955709787847921.
Reference Type
BACKGROUND
Greco R, Demartini C, Zanaboni AM, Piomelli D, Tassorelli C. Endocannabinoid System and Migraine Pain: An Update. Front Neurosci. 2018 Mar 19;12:172. doi: 10.3389/fnins.2018.00172. eCollection 2018.
Reference Type
BACKGROUND
Greco R, Demartini C, Zanaboni AM, Tumelero E, Reggiani A, Misto A, Piomelli D, Tassorelli C. FAAH inhibition as a preventive treatment for migraine: A pre-clinical study. Neurobiol Dis. 2020 Feb;134:104624. doi: 10.1016/j.nbd.2019.104624. Epub 2019 Oct 17.
Reference Type
BACKGROUND
La Porta C, Bura SA, Llorente-Onaindia J, Pastor A, Navarrete F, Garcia-Gutierrez MS, De la Torre R, Manzanares J, Monfort J, Maldonado R. Role of the endocannabinoid system in the emotional manifestations of osteoarthritis pain. Pain. 2015 Oct;156(10):2001-2012. doi: 10.1097/j.pain.0000000000000260.
Reference Type
BACKGROUND
Centonze D, Battistini L, Maccarrone M. The endocannabinoid system in peripheral lymphocytes as a mirror of neuroinflammatory diseases. Curr Pharm Des. 2008;14(23):2370-42. doi: 10.2174/138161208785740018.
Reference Type
BACKGROUND
Sarchielli P, Pini LA, Coppola F, Rossi C, Baldi A, Mancini ML, Calabresi P. Endocannabinoids in chronic migraine: CSF findings suggest a system failure. Neuropsychopharmacology. 2007 Jun;32(6):1384-90. doi: 10.1038/sj.npp.1301246. Epub 2006 Nov 22.
Reference Type
BACKGROUND
Arosio B, Bulbarelli A, Bastias Candia S, Lonati E, Mastronardi L, Romualdi P, Candeletti S, Gussago C, Galimberti D, Scarpini E, Dell'Osso B, Altamura C, MacCarrone M, Bergamaschini L, D'Addario C, Mari D. Pin1 contribution to Alzheimer's disease: transcriptional and epigenetic mechanisms in patients with late-onset Alzheimer's disease. Neurodegener Dis. 2012;10(1-4):207-11. doi: 10.1159/000333799. Epub 2012 Jan 17.
Reference Type
BACKGROUND
Van der Schueren BJ, Van Laere K, Gerard N, Bormans G, De Hoon JN. Interictal type 1 cannabinoid receptor binding is increased in female migraine patients. Headache. 2012 Mar;52(3):433-40. doi: 10.1111/j.1526-4610.2011.02030.x. Epub 2011 Nov 11.
Reference Type
BACKGROUND
Perrotta A, Arce-Leal N, Tassorelli C, Gasperi V, Sances G, Blandini F, Serrao M, Bolla M, Pierelli F, Nappi G, Maccarrone M, Sandrini G. Acute reduction of anandamide-hydrolase (FAAH) activity is coupled with a reduction of nociceptive pathways facilitation in medication-overuse headache subjects after withdrawal treatment. Headache. 2012 Oct;52(9):1350-61. doi: 10.1111/j.1526-4610.2012.02170.x. Epub 2012 Jun 1.
Reference Type
BACKGROUND
Frieling H, Albrecht H, Jedtberg S, Gozner A, Lenz B, Wilhelm J, Hillemacher T, de Zwaan M, Kornhuber J, Bleich S. Elevated cannabinoid 1 receptor mRNA is linked to eating disorder related behavior and attitudes in females with eating disorders. Psychoneuroendocrinology. 2009 May;34(4):620-4. doi: 10.1016/j.psyneuen.2008.10.014. Epub 2008 Nov 28.
Reference Type
BACKGROUND
Greco R, Bandiera T, Mangione AS, Demartini C, Siani F, Nappi G, Sandrini G, Guijarro A, Armirotti A, Piomelli D, Tassorelli C. Effects of peripheral FAAH blockade on NTG-induced hyperalgesia--evaluation of URB937 in an animal model of migraine. Cephalalgia. 2015 Oct;35(12):1065-76. doi: 10.1177/0333102414566862. Epub 2015 Jan 21.
Reference Type
BACKGROUND
Greco R, Gasperi V, Sandrini G, Bagetta G, Nappi G, Maccarrone M, Tassorelli C. Alterations of the endocannabinoid system in an animal model of migraine: evaluation in cerebral areas of rat. Cephalalgia. 2010 Mar;30(3):296-302. doi: 10.1111/j.1468-2982.2009.01924.x. Epub 2010 Feb 1.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ES2020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Efficacy of OnabotulinumtoxinA in Migraine
NCT04578782
COMPLETED
PHASE2
Plasma Levels of CGRP and Expression of Specific microRNAs in Blood Cells of Episodic and Chronic Migraine Subjects
NCT04473976
COMPLETED
Effectiveness and Acceptability of MINDFULNESS by Smartphone, for Patients with Chronic Migraine and Medication Overuse
NCT04389372
COMPLETED
PHASE4
Psychological and Biological Markers of Refractory Migraine
NCT05046119
UNKNOWN
Treatment of Episodic Migraine With AURICular Neuromodulation
NCT06623188
RECRUITING
NA
Presence of Signs of Central Sensitization in Episodic and Chronic Migraine
NCT05162664
COMPLETED
NA
Efficacy of Inhaled Cannabis for Acute Migraine Treatment
NCT04360044
COMPLETED
PHASE2
Brain Connectome for Acupuncture-treated Migraine Patients
NCT04157192
UNKNOWN
NA
Investigation and Modulation of the Central Mu-Opioid Mechanism in Migraine (in Vivo)
NCT05769348
RECRUITING
NA
Cannabis for the Prophylactic Treatment of Migraine
NCT03972124
NOT_YET_RECRUITING
PHASE2
HD-EEG Connectivity Changes in Migraine Patients Undergoing Treatment With Anti-CGRP mAbs
NCT06155123
RECRUITING
Chronic Migraines and Neurofdeeback Mindfulness
NCT06342219
NOT_YET_RECRUITING
NA
Role of Specific microRNAs in Cluster Headache
NCT06503328
RECRUITING
Study of the Molecular Genetics of Menstrual Migraine
NCT00904150
COMPLETED
Improvement the Anti-migraine Treatment Efficacy by Tailoring the Drug to Individual's Pain Modulation Profile
NCT01470339
COMPLETED
NA
Feasibility and Effectiveness of Home-behavioral Program for Adolescents With Migraine
NCT04604977
COMPLETED
NA
A Functional MRI Study on Erenumab Treatment Effects in Episodic Migraine Patients
NCT03977649
COMPLETED
PHASE4
Neurophysiological and Biomolecular Effects of Atogepant in Episodic Migraine
NCT06882122
RECRUITING
Mechanistic Studies of Psilocybin in Headache Disorders
NCT06464367
RECRUITING
EARLY_PHASE1
miR-155 Expression in Episodic and Chronic Migraine
NCT05891808
UNKNOWN
KETOMIGRAINE: Ketogenic Diet in Drug-resistant Chronic Migraineurs
NCT05313503
UNKNOWN
NA
Investigation and Modulation of the Mu-Opioid Mechanisms in Migraine (in Vivo)
NCT02964741
TERMINATED
NA
Multiparametric MRI Study of Endogenous Analgesia and Prediction the Efficacy of Migraine Pharmacological Prevention
NCT01470352
COMPLETED
NA
Searching for Novel Biological Phenotypes in Migraine Patients Resistant to Treatments
NCT06562413
RECRUITING
The Efficacy of Neurofeedback Mindfulness in Migraine Management
NCT06342232
COMPLETED
NA